Fortress Biotech, Inc.
NASDAQ:FBIOBiotechnology
-$0.06 today
- Market cap
- $63.03M
- Beta
- 1.23
- P/E (TTM)
- 0.7
- EPS (TTM)
- $4.05
Volume 0.41M
Average 0.43M
FBIO Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Fortress Biotech, Inc.NASDAQ: FBIO
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin narrows to 54.2%
Gross margin was 54.2% in Q1 FY2026, down 9.3 pp from a year earlier. On a trailing-twelve-month basis it was 64.5%, up 3.3 pp year over year. Over 3 fiscal years it widened by 7.6 pp.
Context
- Gross margin widened in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 66.9%
- Year-over-year change
- +3.1pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 66.9% | +3.1pp |
| FY2024 | 2024-12-31 | 63.8% | -9.1pp |
| FY2023 | 2023-12-31 | 72.9% | +13.5pp |
| FY2022 | 2022-12-31 | 59.4% | +6.0pp |
| FY2021 | 2021-12-31 | 53.4% | — |
Gross Margin vs competitors
How FBIO compares with its peers on the latest reported figures
- FBIO's LTM Mar 2026 gross margin of 64.5% is the 3rd highest of the 5 companies compared; the peer median is 60.4%.
- Its year-over-year change of +3.3 pp is the highest of 4, against a peer median of -4.9 pp.
- Over three fiscal years its change of +7.6 pp compares with a peer median of -4.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 100.0% | +0.0 pp | +0.0 pp | |
| LTM Mar 2026 | 92.4% | -7.6 pp | -27.8 pp | |
| LTM Mar 2026 | 64.5% | +3.3 pp | +7.6 pp | |
| LTM Apr 2026 | 28.4% | -4.9 pp | -8.3 pp | |
| LTM Jun 2024 | -14.6% | — | +0.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding FBIO) | 60.4% | -4.9 pp | -4.1 pp | |
Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 68.79M | 75.74M | 84.51M | 57.68M | 63.26M |
| Cost of Revenue | 32.08M | 30.78M | 22.89M | 20.88M | 20.92M |
| Gross Profit | 36.71M | 44.97M | 61.62M | 36.8M | 42.34M |
| Gross Margin | 53.4% | 59.4% | 72.9% | 63.8% | 66.9% |
| Research & Development | 128.87M | 134.88M | 106.07M | 56.88M | 11.9M |
| Selling, General & Admin | 86.84M | 113.66M | 90.98M | 87.73M | 96.4M |
| Operating Expenses | 225.25M | 248.53M | 203.96M | 147.18M | 112.56M |
| Depreciation & Amortization | 6.79M | 9.35M | 6M | 4.46M | 4.66M |
| EBITDA | (146.17M) | (193.69M) | (135.72M) | (104.49M) | (20.17M) |
| EBITDA Margin | -212.5% | -255.7% | -160.6% | -181.2% | -31.9% |
| Operating Income | (188.54M) | (203.56M) | (142.34M) | (110.38M) | (70.22M) |
| Operating Margin | -274.1% | -268.8% | -168.4% | -191.4% | -111.0% |
| Interest Income | 649K | 1.4M | 3M | 2.68M | 2.49M |
| Interest Expense | 15.31M | 13.64M | 12.52M | 9.93M | 8.71M |
| Other Income / Expenses | 24.19M | (9.9M) | (11.29M) | (10.16M) | 36.69M |
| Income Before Tax | (164.35M) | (213.46M) | (153.63M) | (120.54M) | (33.54M) |
| Pre-Tax Margin | -238.9% | -281.8% | -181.8% | -209.0% | -53.0% |
| Income Tax Expense | 473K | 449K | 521K | 312K | (620K) |
| Net Income | (64.7M) | (86.58M) | (60.64M) | (46M) | 6.82M |
| Net Margin | -94.1% | -114.3% | -71.7% | -79.8% | 10.8% |
| EPS (Basic) | (11.85) | (14.55) | (8.47) | (2.69) | (0.07) |
| EPS (Diluted) | (11.85) | (14.55) | (8.47) | (2.69) | (0.07) |
| Weighted Avg Shares | 5.45M | 5.93M | 8.11M | 20.78M | 27.9M |
| Weighted Avg Shares (Diluted) | 5.45M | 5.93M | 8.11M | 20.78M | 279.02M |
Fortress Biotech, Inc.
NASDAQ:FBIO
Intrinsic Alpha fair value
Locked
Current Price
$1.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.